Friday, October 27, 2023 12:27:23 PM
sentiment_stocks,
Based on the numbers, they did have control patients enrolled. They had 87(?) total, 29 control, planned for to be enrolled and only 17 total remained unenrolled and Germany was very likely the last to fully enroll treatment arm patients. That means 10 were very likely enrolled and of those several likely PFS evented quickly along with possible pseudoprogression treatment response in the treatment arm which would have been seen as an immediate potential safety issue by German regulators and FDA. Some of those control patients probably never fully recovered while the treatment arm patients did better. Remember that the interim data from 2018 suggested that some of the long livers came from low absolute lymphocyte count patients and those could have been enrolled in Germany in late 2014 to early 2015 ; ). Best wishes.
Based on the numbers, they did have control patients enrolled. They had 87(?) total, 29 control, planned for to be enrolled and only 17 total remained unenrolled and Germany was very likely the last to fully enroll treatment arm patients. That means 10 were very likely enrolled and of those several likely PFS evented quickly along with possible pseudoprogression treatment response in the treatment arm which would have been seen as an immediate potential safety issue by German regulators and FDA. Some of those control patients probably never fully recovered while the treatment arm patients did better. Remember that the interim data from 2018 suggested that some of the long livers came from low absolute lymphocyte count patients and those could have been enrolled in Germany in late 2014 to early 2015 ; ). Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
